Key takeaways from the Fall 2025 AARR meeting are presented, which brought together academic, clinical, and industry leaders to discuss and explore the current advances in the heterogeneity and co‐pathologies of AD and their implications for diagnosis, clinical trial design, and precision treatment strategies.
M. Tansey, S. Bozeat, Peter Ackerman et al.· Alzheimer's & Dementia· 0 citations
As life expectancy increases worldwide, the proportion of people aged 65 and older is expected to double by 2050 and these global demographic shifts will be accompanied by an increase in age-related neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD). AD is the leading cause of dementia w...
C. Tropis, Janna Jernigan Posey, M. Tansey et al.· Molecular Neurodegeneration· 0 citations
Introduction Parkinson’s disease (PD) is increasingly recognized as a neurological disorder characterized not only by neurodegeneration but also by chronic immune dysregulation across the lifespan. Although the initiating events underlying PD remain unclear, accumulating evidence suggests that inflammatory processes ma...
Andrea R. Merchak, Mary K. Herrick, M. Houser et al.· Frontiers in Cellular Neuros...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
